These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36729640)

  • 1. Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
    Li Y
    J Obstet Gynaecol; 2023 Dec; 43(1):2171282. PubMed ID: 36729640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.
    Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M
    World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
    Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
    BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
    J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
    Cheng H; Yang J; Liu H; Xiang Y
    Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
    Zhou S; Jiang Y; Luo C; Yuan L
    Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
    Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
    Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy.
    Rognoni C; Lorusso D; Costa F; Armeni P
    Adv Ther; 2024 Apr; 41(4):1385-1400. PubMed ID: 38329713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
    Yang Y; Du N; Xie L; Jiang J; Mo J; Hong J; Mao D; Ng DM; Shi H
    World J Surg Oncol; 2020 Jul; 18(1):151. PubMed ID: 32622363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials.
    Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B
    J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
    BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    Kaneko M
    Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
    Lee B; Chang SJ; Kwon BS; Son JH; Lim MC; Kim YH; Lee SW; Choi CH; Eoh KJ; Lee JY; Suh DH; Kim YB
    PLoS One; 2023; 18(11):e0294647. PubMed ID: 37976295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.
    Pan YE; Hood A; Ahmad H; Altwerger G
    Ann Pharmacother; 2023 Oct; 57(10):1162-1171. PubMed ID: 36651235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.